Albert Morales

Grup de recerca

Senyalització hepatocel·lular i càncer Group leader (R4-IIBB-CSIC)

amorales@clinic.cat 0000-0001-8702-2269

Publicacions destacades

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

Autors:
Cucarull, Blanca; Tutusaus, Anna; Subias, Miguel; Stefanovic, Milica; Hernaez-Alsina, Tania;

(...)

Garcia de Frutos, Pablo; Mari, Montserrat; Colell, Anna; Bruix, Jordi; Morales, Albert.

Referència: Cancers 2020.
Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress

Autors:
de Dios C; Bartolessis I; Roca-Agujetas V; Barbero-Camps E; Mari M;

Morales A; Colell A .

Referència: Redox Biology 2019.
Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a re-sensitizing agent.

Autors:
Piulats, Josep M; Vidal, August; Garcia-Rodriguez, Francisco J; Munoz, Clara; Nadal, Marga;

(...)

Morales, Albert; Vinals, Francesc; Garcia-del-Muro, Xavier; Ceron, Julian; Villanueva, Alberto.

Referència: Clinical Cancer Research 2018.
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

Autors:
Tutusaus A; Stefanovic M; Boix L; Cucarull B; Zamora A;

(...)

Fernandez-Checa JC; Marí M; Colell A; Bruix J; Morales A.

Referència: Oncotarget 2018.
Differential role of cathepsins S and B in hepatic APC-mediated NKT cell activation and cytokine secretion

Autors:
Pulido Á; de Gregorio E; Chandra S; Colell A; Morales A;

Kronenberg M; Marí M.

Referència: Frontiers In Immunology 2018.
Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion.

Autors:
Barbero-Camps E; Roca-Agujetas V; Bartolessis I; de Dios C; Fernández-Checa JC;

Marí M; Morales A; Hartmann T; Colell A .

Referència: Autophagy 2018.
Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation.

Autors:
de Mingo Á; de Gregorio E; Moles A; Tarrats N; Tutusaus A;

Colell A; Fernandez-Checa JC; Morales A; Marí M .

Referència: Cell Death & Disease 2016.
Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis

Autors:
Mari, Montserrat; Tutusaus, Anna; Garcia de Frutos, Pablo; Morales, Albert;

Referència: Journal Of Hepatology 2016.
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma

Autors:
Stefanovic, Milica; Tutusaus, Anna; Martinez-Nieto, Guillermo A; Barcena, Cristina; de Gregorio, Estefania;

(...)

Colell, Anna; Mari, Montserrat; Garcia-Ruiz, Carmen; Fernandez-Checa, Jose C; Morales, Albert.

Referència: Oncotarget 2016.
Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation

Autors:
Barcena, Cristina; Stefanovic, Milica; Tutusaus, Anna; Joannas, Leonel; Menendez, Anghara;

(...)

Caballeria, Joan; Rothlin, Carla V; Fernandez-Checa, Jose C; Garcia de Frutos, Pablo; Morales, Albert.

Referència: Journal Of Hepatology 2015.

Projectes destacats

The interplay between ACE2 and AXL systems to predict COVID-19 disease severity and outcomes.

Investigador/a principal: Albert Morales Munoz

Finançador: Marato de TV3

Codi: 202133-32

Durada: 01/10/2021 - 31/12/2024
TERAPIAS MOLECULARES DIRIGIDAS AL MICROAMBIENTE EN FIBROSIS Y CANCER

Investigador/a principal: Albert Morales Munoz

Finançador: Ministerio de Ciencia e Innovación (Programa financiador competitivo)

Codi: RTI2018-095672-B-I00

Durada: 01/01/2019 - 30/06/2022

Albert Morales

Grup de recerca

Publicacions destacades

Projectes destacats

The interplay between ACE2 and AXL systems to predict COVID-19 disease severity and outcomes.

TERAPIAS MOLECULARES DIRIGIDAS AL MICROAMBIENTE EN FIBROSIS Y CANCER

Subscriu-te a la Newsletter del Clínic